Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: J Rheumatol. 2018 Mar 1;45(5):671–677. doi: 10.3899/jrheum.161554

Figure 2. Long-term renal survival based on remission category at 24 months post biopsy: A. mALMS criteria (ordinal) B. mBLISS-LN criteria (ordinal) C. proteinuria (binary criteria).

Figure 2

CR, complete remission; mALMS, modified Aspreva Lupus Management Study; mBLISS-LN, modified Belimumab International Lupus Nephritis Study; PR, partial remission; Pr:Cr, protein:creatinine Cut-off of 0.8g/day selected due to a recent publication (16)